BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kirino S, Tamaki N, Kurosaki M, Inada K, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Izumi N. Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment. J Viral Hepat 2021;28:787-94. [PMID: 33484033 DOI: 10.1111/jvh.13473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Kirino S, Tamaki N, Kurosaki M, Izumi N. Reply to Wang et al. J Viral Hepat 2021;28:1335-6. [PMID: 34056812 DOI: 10.1111/jvh.13556] [Reference Citation Analysis]
2 Wang S, Fang S, Liu Y. The 5-year cumulative incidence of HCC development and treatment regimen in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment. J Viral Hepat 2021;28:1333-4. [PMID: 34051028 DOI: 10.1111/jvh.13553] [Reference Citation Analysis]
3 Tamaki N, Kurosaki M, Kirino S, Izumi N. Diagnostic accuracy of hepatocellular carcinoma risk prediction models during antiviral therapy in chronic hepatitis B patients. Hepatol Res 2021;51:1170-1. [PMID: 34724296 DOI: 10.1111/hepr.13684] [Reference Citation Analysis]